# FDA Approves Novocure Optune Pax Medical Device for Locally Advanced Pancreatic Cancer

> fda · REPORTED · 2026-02-12

The FDA approved Optune Pax, a wearable medical device developed by Novocure that delivers tumor treating fields via alternating electrical fields to the abdomen for patients with locally advanced pancreatic cancer. The device uses electrically insulated adhesive patches connected to an electric field generator to physically disrupt rapid cancer cell division with minimal damage to healthy tissue.

About Novocure (Optune Pax): Novocure is a global oncology company developing and commercializing tumor treating fields therapy delivered through wearable medical devices, targeting difficult-to-treat solid tumors including glioblastoma and pancreatic cancer.

- Company: Novocure (Optune Pax)
- Sector: medical devices
- Primary source: https://www.cancertherapyadvisor.com/features/fda-oncology-drug-approvals-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.